Under the guidance of ADVISO PARTNERS, AQUILAB’s shareholder managers have sold 100% of their company’s capital to COEXYA GROUP, an ARGOS WITYU holding. AQUILAB will become part of COEXYA GROUP’s health division.
COEXYA GROUP is one of France’s leading independent software publishing and data processing companies.
AQUILAB, an SME based in France’s Nord department with around 30 employees, provides nearly 350 healthcare centres in France and abroad with software solutions guaranteeing the quality of radiotherapy and medical imaging equipment, as well as a platform which manage data from clinical trials. COEXYA GROUP’s offer includes CONSORE, a solution enabling doctors to examine information from the records of patients undergoing treatment, and more general data, to improve knowledge in oncology. COEXYA is chaired by Philippe LE CALVE and currently employs 700 people in Lyon, Brest, Paris and Rennes. It generated nearly €70 million in revenue in 2021 with 370 customers.
With the acquisition of GEOMOD last December, COEXYA GROUP and ARGOS WITYU strengthened the Luxembourg IT services and software publishing group’s geolocation activity. The two companies subsequently maintained a proactive approach to identifying targets in order to consolidate one of COEXYA’s five other branches. Homing in on the healthcare sector, they turned their focus on Lille-based AQUILAB which develops oncology solutions of 20 years’ standing, co-founded by David GIBON and Henri HOUZET.
Philippe LE CALVE, Chairman and Chief Executive Officer of COEXYA: “I am particularly pleased that Coexya is acquiring Aquilab, a company active in the healthcare sector. Our customers will be able to take advantage of an expanded range of services in France and abroad. We are delighted to welcome Aquilab’s employees into our group through a transaction that will also enable us to develop in the region of Lille.”
David GIBON, Chairman and Chief Executive Officer of AQUILAB: “For more than 20 years, we have been providing innovative products devoted to improving the quality of cancer treatment. The merger with Coexya will enable us to strengthen our expertise in data and AI to step up our development in predictive medicine. Aquilab and Coexya have customers in common and share the same values. By leveraging these synergies, we will be able to propose new solutions and provide better treatment to people suffering from cancer.”
Guillaume CAPELLE, Partner at ADVISO PARTNERS: “We are very pleased to have contributed to the success of this merger in a business sector that we know well and are passionate about. Pooling the technical expertise of the AQUILAB and COEXYA teams will open up new horizons, provide additional resources and help make further progress for the benefit of patients.”